CL2020001943A1 - Biomarcador predictivo de terapia de linfocitos infiltrates de tumor y sus usos - Google Patents
Biomarcador predictivo de terapia de linfocitos infiltrates de tumor y sus usosInfo
- Publication number
- CL2020001943A1 CL2020001943A1 CL2020001943A CL2020001943A CL2020001943A1 CL 2020001943 A1 CL2020001943 A1 CL 2020001943A1 CL 2020001943 A CL2020001943 A CL 2020001943A CL 2020001943 A CL2020001943 A CL 2020001943A CL 2020001943 A1 CL2020001943 A1 CL 2020001943A1
- Authority
- CL
- Chile
- Prior art keywords
- patients
- biomarker
- tumor infiltrating
- infiltrating lymphocyte
- therapy
- Prior art date
Links
- 238000002560 therapeutic procedure Methods 0.000 title abstract 2
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 title abstract 2
- 239000000092 prognostic biomarker Substances 0.000 title 1
- 102100029215 Signaling lymphocytic activation molecule Human genes 0.000 abstract 6
- 239000000090 biomarker Substances 0.000 abstract 3
- 230000014509 gene expression Effects 0.000 abstract 3
- 108010074687 Signaling Lymphocytic Activation Molecule Family Member 1 Proteins 0.000 abstract 2
- 238000011467 adoptive cell therapy Methods 0.000 abstract 2
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 238000001802 infusion Methods 0.000 abstract 1
- 238000002955 isolation Methods 0.000 abstract 1
- 230000002018 overexpression Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46449—Melanoma antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/65—MicroRNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Developmental Biology & Embryology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente invención se relaciona con un biomarcador útil en terapia celular adoptiva. El biomarcador en cuestión es el CD150, también denominado SLAM o SLAMF1. Aquí demostramos que la expresión del CD150 en productos de infusión de linfocitos infiltrantes de tumor se correlaciona con la tasa de respuesta observada en esos pacientes. La expresión alta de CD150 se encuentra en pacientes que continúan teniendo una respuesta completa y la expresión baja en pacientes que no responden a la terapia. La invención se refiere al uso del biomarcador para predecir la tasa de respuesta o estratificar a los pacientes para el tratamiento. También cubre el aprovechamiento de este receptor en regímenes de terapia celular adoptiva en general, que incluye, entre otros, la sobreexpresión del receptor en poblaciones de células T o el aislamiento de células que expresan CD150 en un esfuerzo por aumentar la eficacia.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1801067.8A GB201801067D0 (en) | 2018-01-23 | 2018-01-23 | Biomarkers predictive of tumour infiltrating lymphocyte therapy and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2020001943A1 true CL2020001943A1 (es) | 2021-02-26 |
Family
ID=61283558
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2020001943A CL2020001943A1 (es) | 2018-01-23 | 2020-07-23 | Biomarcador predictivo de terapia de linfocitos infiltrates de tumor y sus usos |
Country Status (22)
Country | Link |
---|---|
US (1) | US20210000872A1 (es) |
EP (2) | EP4233883A3 (es) |
JP (1) | JP2021511079A (es) |
KR (1) | KR20200112915A (es) |
CN (1) | CN111886335A (es) |
AU (1) | AU2019213201A1 (es) |
BR (1) | BR112020014998A2 (es) |
CA (1) | CA3089294A1 (es) |
CL (1) | CL2020001943A1 (es) |
CO (1) | CO2020010266A2 (es) |
CR (1) | CR20200361A (es) |
EA (1) | EA202091753A1 (es) |
EC (1) | ECSP20050981A (es) |
ES (1) | ES2948969T3 (es) |
GB (1) | GB201801067D0 (es) |
IL (1) | IL276167A (es) |
MA (1) | MA51705A (es) |
MX (1) | MX2020007728A (es) |
PE (1) | PE20210843A1 (es) |
PH (1) | PH12020551110A1 (es) |
SG (1) | SG11202006875VA (es) |
WO (1) | WO2019145711A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201700621D0 (en) | 2017-01-13 | 2017-03-01 | Guest Ryan Dominic | Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue |
GB201910605D0 (en) * | 2019-07-24 | 2019-09-04 | Immetacyte Ltd | Tumour infltracting lymphocyte therapy amd uses thereo |
IL294098A (en) | 2019-12-20 | 2022-08-01 | Instil Bio Uk Ltd | Devices and methods for isolating lymphocytes infiltrating tumors and their use |
CA3205464A1 (en) | 2020-12-18 | 2022-06-23 | Instil Bio (Uk) Limited | Processing of tumor infiltrating lymphocytes |
EP4263807A2 (en) | 2020-12-18 | 2023-10-25 | Instil Bio (Uk) Limited | Processing of tumor infiltrating lymphocytes |
WO2022130016A1 (en) | 2020-12-18 | 2022-06-23 | Instil Bio (Uk) Limited | Tumor infiltrating lymphocytes and anti-cd47 therapeutics |
US20220313806A1 (en) | 2021-03-25 | 2022-10-06 | Iovance Biotherapeutics, Inc. | Methods and compositions for t-cell coculture potency assays and use with cell therapy products |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2386270A1 (en) | 1999-10-15 | 2001-04-26 | University Of Massachusetts | Rna interference pathway genes as tools for targeted genetic interference |
US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
WO2001096584A2 (en) | 2000-06-12 | 2001-12-20 | Akkadix Corporation | Materials and methods for the control of nematodes |
EP1777523A1 (en) | 2005-10-19 | 2007-04-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method |
SG11201508585PA (en) * | 2013-04-18 | 2015-11-27 | Tilt Biotherapeutics Oy | Enhanced adoptive cell therapy |
CA2943389C (en) * | 2014-03-20 | 2023-10-31 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Tumor-infiltrating lymphocytes for adoptive cell therapy |
WO2017179015A1 (en) * | 2016-04-15 | 2017-10-19 | Glaxosmithkline Intellectual Property Development Limited | Compositions for the treatment of cancer |
-
2018
- 2018-01-23 GB GBGB1801067.8A patent/GB201801067D0/en not_active Ceased
-
2019
- 2019-01-23 KR KR1020207024069A patent/KR20200112915A/ko not_active Application Discontinuation
- 2019-01-23 WO PCT/GB2019/050188 patent/WO2019145711A1/en unknown
- 2019-01-23 ES ES19702676T patent/ES2948969T3/es active Active
- 2019-01-23 CN CN201980020942.7A patent/CN111886335A/zh active Pending
- 2019-01-23 MX MX2020007728A patent/MX2020007728A/es unknown
- 2019-01-23 EP EP23177650.1A patent/EP4233883A3/en active Pending
- 2019-01-23 AU AU2019213201A patent/AU2019213201A1/en not_active Abandoned
- 2019-01-23 JP JP2020560612A patent/JP2021511079A/ja not_active Ceased
- 2019-01-23 MA MA051705A patent/MA51705A/fr unknown
- 2019-01-23 SG SG11202006875VA patent/SG11202006875VA/en unknown
- 2019-01-23 BR BR112020014998-5A patent/BR112020014998A2/pt unknown
- 2019-01-23 PE PE2020001006A patent/PE20210843A1/es unknown
- 2019-01-23 CA CA3089294A patent/CA3089294A1/en active Pending
- 2019-01-23 EP EP19702676.8A patent/EP3743511B1/en active Active
- 2019-01-23 CR CR20200361A patent/CR20200361A/es unknown
- 2019-01-23 EA EA202091753A patent/EA202091753A1/ru unknown
-
2020
- 2020-07-20 IL IL276167A patent/IL276167A/en unknown
- 2020-07-22 PH PH12020551110A patent/PH12020551110A1/en unknown
- 2020-07-22 US US16/935,612 patent/US20210000872A1/en not_active Abandoned
- 2020-07-23 CL CL2020001943A patent/CL2020001943A1/es unknown
- 2020-08-20 CO CONC2020/0010266A patent/CO2020010266A2/es unknown
- 2020-08-21 EC ECSENADI202050981A patent/ECSP20050981A/es unknown
Also Published As
Publication number | Publication date |
---|---|
JP2021511079A (ja) | 2021-05-06 |
PH12020551110A1 (en) | 2021-07-05 |
EP3743511B1 (en) | 2023-06-07 |
US20210000872A1 (en) | 2021-01-07 |
ES2948969T3 (es) | 2023-09-22 |
AU2019213201A1 (en) | 2020-08-06 |
IL276167A (en) | 2020-09-30 |
CR20200361A (es) | 2021-01-13 |
GB201801067D0 (en) | 2018-03-07 |
SG11202006875VA (en) | 2020-08-28 |
CN111886335A (zh) | 2020-11-03 |
CA3089294A1 (en) | 2019-08-01 |
EP3743511C0 (en) | 2023-06-07 |
PE20210843A1 (es) | 2021-05-10 |
MX2020007728A (es) | 2020-10-05 |
WO2019145711A1 (en) | 2019-08-01 |
EP4233883A2 (en) | 2023-08-30 |
EP3743511A1 (en) | 2020-12-02 |
MA51705A (fr) | 2020-12-02 |
KR20200112915A (ko) | 2020-10-05 |
CO2020010266A2 (es) | 2020-10-30 |
BR112020014998A2 (pt) | 2020-12-29 |
ECSP20050981A (es) | 2021-01-29 |
EA202091753A1 (ru) | 2020-09-23 |
EP4233883A3 (en) | 2023-10-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2020001943A1 (es) | Biomarcador predictivo de terapia de linfocitos infiltrates de tumor y sus usos | |
ECSP22004616A (es) | Terapia con linfocitos de infiltración tumoral y sus usos | |
CO2017004932A2 (es) | Métodos para seleccionar una línea de células t y donador de la misma para terapia celular adoptiva | |
CO2017011197A2 (es) | Terapia de combinación fgfr/pd-1 para el tratamiento del cancer | |
CL2015002941A1 (es) | Usos terapéuticos de empaglifozina | |
GT201500249A (es) | Terapia de combinación | |
UY35313A (es) | Antiadhesion de leucocitos para mitigar los potenciales eventos adversos causados por los dominios de unión específicos de cd3 | |
ES2422739T3 (es) | Composición para el diagnóstico, prevención o tratamiento de enfermedades relacionadas con células que expresan IL-8 o GRO-, que comprende MSC de UCB | |
BR112019021857A2 (pt) | Métodos e composições de célula t aperfeiçoada | |
AR092899A1 (es) | Uso de masitinib para el tratamiento del cancer en subpoblaciones de pacientes identificados que utilizan factores de prediccion | |
PE20170324A1 (es) | Anticuerpos dirigidos contra cd127 | |
CL2018002069A1 (es) | Biomarcadores para copanlisib | |
BR112015008143A2 (pt) | complexos, polipeptídeo e/ou polinucleotídeo isolado e purificado, composições, métodos para preparar, produzir ou obter complexos, para expandir e/ou desenvolver populações de células t autorreativas antipatogênicas e/ou para tratar esclerose múltipla ou distúrbio relacionado em sujeito com essa necessidade, kit e uso de complexos, de polipeptídeo e/ou de polinucleotídeo isolados e purificados e/ou de composições | |
BR112021022363A2 (pt) | Composições e métodos para fabricação de células t | |
BR112016029558A2 (pt) | terapia de células-tronco em patologias endometriais | |
AR104598A1 (es) | Métodos para tratar trastornos linfoproliferativos asociados al virus de epstein-barr por terapia con células t | |
AR087363A1 (es) | Uso del anticuerpo i-3859 para la deteccion y diagnostico de los canceres | |
BR112017003552A2 (pt) | ?métodos para tratar caquexia, para tratar saciedade precoce, para aumentar o tempo de sobrevida, para melhorar a qualidade de vida e para aumentar a massa corporal total? | |
AR109279A1 (es) | Anticuerpos anti plazomicina y métodos de uso de los mismos | |
MX2021007951A (es) | Ensayo multiplexado y metodos de uso del mismo. | |
EA201890623A1 (ru) | Рациональная комбинированная терапия для лечения рака | |
CL2022001459A1 (es) | Célula vector adyuvante artificial con contenido de ny-eso-1 para el tratamiento del cancer | |
BR112016020043A2 (pt) | composições e métodos para a identificação de malignidades de linfócitos b responsivas à terapia de depleção de linfócitos b | |
AR118336A1 (es) | Métodos para tratar pacientes con cáncer con inhibidores de farnesiltransferasa | |
CO2019006926A2 (es) | Nuevos receptores de células t y terapia inmunológica que los utiliza |